Estimating the impact of ENESTnd trial data.

A new report from Sermo surveyed 141 Hematologists/Oncologists to measure the impact of ENESTnd trial data on Oncologist’s use of Tasigna, Sprycel, and Gleevec in newly diagnosed CML patients. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.

Highlights of the report include:

• Insight into changing landscape of treatments for newly diagnosed CML patients.
• Physicians’ perception of cytogenetic and molecular measures in predicting long-term outcomes and their impact on choice of CML therapy.
• Off-label use of Sprycel and Tasigna.
• Physicians’ impression of Tasigna’s front line data versus Gleevec in newly diagnosed Ph+ CML patients.
• Impact of ENESTnd data in evolving treatment choices for front line patients.

Fill out the form below to learn more about this report. This 30-slide PowerPoint presentation includes the poll results and full transcript of the physician comments. Lean more about Sermo Event Reports.

Have questions?

Call us: 877-778-3963